GDF15 and cardiovascular disorder: No differences were observed pre- and post-treatment in plasma GDF-15 and CRP, though participants with CRP indicative of an elevated cardiovascular disease risk (hsCRP ≥ 3μg/ml), had a reduction in CRP post-supplementation (p = 0.0195).